Prof. Gioacchino Tedeschi is Full Professor of Neurology and Chief of the First Division of Neurology, University of Campania “Luigi Vanvitelli” in Naples (Italy) (respectively from 2000 and 2010). He was Research Assistant and Visiting Research Fellow, respectively from 1982 to 1983 and from 1990 to 1992, at the Department of Pharmacology and Therapeutics, University of Cardiff, Cardiff (UK). He was Assistant Professor of Neurology, from 1984 to 1992, and Associate Professor of Neurology, from 1995 to 2000, at the Second University of Naples (Italy). From 1993 to 1996, he was Visiting Scientist at the Neuroimaging Branch, National Institutes of Health, Bethesda, MD, USA. Prof. Tedeschi, whose main areas of research are neuroimaging/clinical trials applied to dementia, headache/migraine, multiple sclerosis, movement disorders and ALS, has been President of the Italian Society of Neurology (SIN) from 2019 to 2021. He is a member of the Italian ALS Genetic (ITALSGEN) Consortium (2010- today) and of the Neuroimaging Society in Amyotrophic Lateral Sclerosis (NiSALS) (2014-today).
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.